Adaptive Biotechnologies Corp
Затворен
23 1.86
Преглед
Промяна на цената на акция
24 ч
Минимум
22.47
Максимум
23.02
Приходи | -6.4M -20M |
|---|---|
Продажби | -807K 71M |
EPS | -0.13 |
Марж на печалбата | -28.24 |
Служители | 624 |
EBITDA | -7.9M -14M |
Препоръки | Силна покупка |
|---|---|
12-месечна прогноза | +6.34% upside |
Пазарна капитализация | 1.3B 3.6B |
|---|---|
Предишно отваряне | 21.14 |
Предишно затваряне | 23 |
Adaptive Biotechnologies Corp Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Adaptive Biotechnologies Corp Прогноза
Ценова цел
By TipRanks
6.34% нагоре
12-месечна прогноза
Среден 24 USD 6.34%
Висок 28 USD
Нисък 20 USD
Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.
Финанси
Продажбени и админисративни разходи
Оперативни разходи
Печалба преди облагане с данъци
Продажби
Разходи за продажби
Брутна печалба от продажби
Разходи за лихви по дълг
EBITDA
Оперативна печалба
$
Относно Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
